Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
NanoViricides Inc (NNVC)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
06/27/2025: NNVC (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
1 Analysts rated it
These Stocks/ETFs, based on Upturn Advisory, have historically outperformed the market, making them a top-tier choice for investors.
Year Target Price $5.25
Year Target Price $5.25
| 1 | Strong Buy |
| 0 | Buy |
| 0 | Hold |
| 0 | Under performing |
| 0 | Sell |
Analysis of Past Performance
Type Stock | Historic Profit -54.65% | Avg. Invested days 25 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 06/27/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 22.50M USD | Price to earnings Ratio - | 1Y Target Price 6.5 |
Price to earnings Ratio - | 1Y Target Price 6.5 | ||
Volume (30-day avg) - | Beta 0.92 | 52 Weeks Range 0.94 - 2.55 | Updated Date 06/29/2025 |
52 Weeks Range 0.94 - 2.55 | Updated Date 06/29/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.69 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -57.38% | Return on Equity (TTM) -99.84% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 17030912 | Price to Sales(TTM) - |
Enterprise Value 17030912 | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA -1.11 | Shares Outstanding 16072000 | Shares Floating 15504658 |
Shares Outstanding 16072000 | Shares Floating 15504658 | ||
Percent Insiders 3.53 | Percent Institutions 9.26 |
Analyst Ratings
Rating 5 | Target Price 5.25 | Buy - | Strong Buy 1 |
Buy - | Strong Buy 1 | ||
Hold - | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
NanoViricides Inc
Company Overview
History and Background
NanoViricides, Inc. was founded in 2003 and is a clinical stage company that is focused on research and development of treatments for virally caused diseases.
Core Business Areas
- Antiviral Drug Development: The company's primary focus is developing antiviral drugs based on its nanoviricide platform technology. This includes research, preclinical studies, and clinical trials.
- Platform Technology Licensing: NanoViricides may also explore licensing its platform technology to other companies for specific antiviral applications, although this appears not to be a current primary business activity.
Leadership and Structure
The company's leadership includes Anil R. Diwan, PhD, President and Executive Chairman. The organizational structure is typical of a small biotechnology firm, with research, development, and administrative departments.
Top Products and Market Share
Key Offerings
- Herpes Nanoviricide Program: This is a key focus area, developing nanoviricides to combat herpes simplex virus (HSV). Clinical trials are ongoing. No market share or revenue data is currently available. Competitors include pharmaceutical companies producing acyclovir, valacyclovir, and similar drugs. Examples include GSK, Teva Pharma.
- COVID-19 Nanoviricide Program: The company has programs aimed at developing nanoviricides to treat COVID-19. Preclinical and early stage development. No market share or revenue data is currently available. Key competitors are Pfizer (Paxlovid), Merck (Molnupiravir), and other companies developing COVID-19 therapeutics.
- Shingles Nanoviricide Program: Developing nanoviricides for treating shingles. Currently in preclinical development. No market share or revenue data available. Competitors include GSK(Shingrix), Merck & Co., Inc.(Zostavax).
Market Dynamics
Industry Overview
The antiviral drug market is large and growing, driven by the emergence of new viral threats and the increasing prevalence of existing viral infections. The market includes pharmaceuticals, vaccines, and other therapeutic interventions.
Positioning
NanoViricides is positioned as an innovator in the antiviral space, utilizing nanotechnology to develop novel therapeutics. However, it is a small player compared to large pharmaceutical companies, and faces significant challenges in bringing its products to market.
Total Addressable Market (TAM)
The global antiviral drug market is estimated at hundreds of billions of USD. NanoViricides aims to capture a portion of this TAM by developing effective nanoviricide-based treatments for specific viral infections.
Upturn SWOT Analysis
Strengths
- Novel nanoviricide platform technology
- Potential for broad-spectrum antiviral activity
- Targeting difficult-to-treat viral infections
Weaknesses
- Limited financial resources
- Early stage of development
- High risk of clinical trial failure
- Reliance on external funding
Opportunities
- Partnerships with larger pharmaceutical companies
- Government funding for antiviral research
- Addressing unmet medical needs in viral infections
- Expanding the application of the nanoviricide platform
Threats
- Competition from established antiviral drugs
- Regulatory hurdles in drug approval
- Patent challenges
- Failure to secure sufficient funding
Competitors and Market Share
Key Competitors
- PFE
- MRK
- GILD
- ABBV
- JNJ
Competitive Landscape
NanoViricides faces intense competition from large pharmaceutical companies with established antiviral drugs and extensive resources. Its competitive advantage lies in its novel nanoviricide platform, but it needs to demonstrate clinical efficacy and secure funding to compete effectively.
Growth Trajectory and Initiatives
Historical Growth: Historical growth is largely reflected in R&D spending and preclinical progress, as the company is not yet generating substantial revenues.
Future Projections: Future growth is dependent on successful clinical trials and eventual commercialization of nanoviricide-based drugs. Analyst projections are highly speculative due to the inherent uncertainties in drug development.
Recent Initiatives: Recent initiatives include advancing clinical trials for herpes nanoviricides and pursuing development of nanoviricides for COVID-19 and other viral infections.
Summary
NanoViricides is a high-risk, high-reward biotechnology company with a promising nanoviricide platform. Its success hinges on positive clinical trial results and securing adequate funding. The company needs to carefully manage its cash burn and navigate the competitive landscape of the antiviral drug market, while also protecting itself from competition.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company Website
- SEC Filings
- Analyst Reports
- Press Releases
Disclaimers:
This analysis is for informational purposes only and should not be considered investment advice. The biotechnology industry is inherently risky, and investors should conduct their own due diligence before making any investment decisions.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About NanoViricides Inc
Exchange NYSE MKT | Headquaters Shelton, CT, United States | ||
IPO Launch date 2005-10-26 | Executive Chairman, President, CEO & Secretary Dr. Anil R. Diwan Ph.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 7 | Website https://www.nanoviricides.com |
Full time employees 7 | Website https://www.nanoviricides.com | ||
NanoViricides, Inc., a clinical stage nano-biopharmaceutical company, discovers, develops, and commercializes drugs for the treatment of viral infections. The company's product portfolio includes NV-387 drug candidate developed for RSV and influenza indications and has completed phase 1a/1b human clinical trial for the evaluation of safety and tolerability; NV-387 as an active ingredient of drug product formulations for the treatment of COVID infections comprising NV-CoV-2 Oral Syrup and NV-CoV-2 Oral Gummies, a semi-solid fixed-dose form, which are in phase 1a/1b human clinical trials for enabling body-weight-based dose titration as is required for pediatric treatments. It also offers NV-387 Solution for injection, infusion, and inhalation to treat severe cases that are not hospitalized and carried out by an injection; and injectable solution that delivered directly into the lungs as a fog created using portable battery operated nebulizer devices, which enables action at infection by a respiratory virus, such as coronaviruses, RSV, influenzas, human meta-pneumovirus, certain adenoviruses, and other infections, that can lead to severe pneumonia. In addition, the company develops NV-HHV-1, a skin cream for the treatment of Shingles rash, which has completed non-clinical pharmacology studies; oral drug with NV-HHV-1 as the active ingredient for the treatment of HSV-1 cold sores and HSV-2 genital ulcers; and other drug candidates in HIVCide program for the treatment of Dengue and Ebola virus, as well as provides Nanoviricide platform technology to treat various types of viruses. NanoViricides, Inc. was incorporated in 2005 and is headquartered in Shelton, Connecticut.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.